The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism

Francesco Andreozzi,Gregory Alexander Raciti,Cecilia Nigro,Gaia Chiara Mannino,Teresa Procopio,Alberto M. Davalli,Francesco Beguinot,Giorgio Sesti,Claudia Miele,Franco Folli
DOI: https://doi.org/10.1186/s12967-016-0985-7
IF: 8.44
2016-07-30
Journal of Translational Medicine
Abstract:Aims/hypothesisPotentiation of glucose-induced insulin secretion is the main mechanism of exenatide (EXE) antidiabetic action, however, increased glucose utilization by peripheral tissues has been also reported. We here studied the effect of EXE on glucose uptake by skeletal muscle cells.Methods2-deoxy-glucose (2DG) uptake and intracellular signal pathways were measured in rat L6 skeletal muscle myotubes exposed to 100 nmol/l EXE for up to 48 h. Mechanisms of EXE action were explored by inhibiting AMPK activity with compound C (CC, 40 μmol/l) or siRNAs (2 μmol/l).ResultsTime course experiments show that EXE increases glucose uptake up to 48 h achieving its maximal effect, similar to that induced by insulin, after 20 min (2- vs 2.5-fold-increase, respectively). Differently from insulin, EXE does not stimulate: (i) IR β-subunit- and IRS1 tyrosine phosphorylation and binding to p85 regulatory subunit of PI-3kinase; (ii) AKT activation; and (iii) ERK1/2 and JNK1/2 phosphorylation. Conversely, EXE increases phosphorylation of α-subunit of AMPK at Thr172 by 2.5-fold (p < 0.01). Co-incubation of EXE and insulin does not induce additive effects on 2DG-uptake. Inhibition of AMPK with CC, and reduction of AMPK protein expression by siRNA, completely abolish EXE-induced 2DG-uptake. Liraglutide, another GLP-1 receptor agonist, also stimulates AMPK phosphorylation and 2DG-uptake. Moreover, EXE stimulates 2DG-uptake also by L6 myotubes rendered insulin-resistant with methylglyoxal. Finally, EXE also induces glucose transporter Glut-4 translocation to the plasma membrane.Conclusions/interpretationIn L6 myotubes, EXE and liraglutide increase glucose uptake in an insulin-independent manner by activating AMPK.
medicine, research & experimental
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore how GLP - 1 receptor agonists, exenatide (EXE) and liraglutide (Lira), increase glucose uptake in skeletal muscle cells through an AMPK (AMP - activated protein kinase)-dependent mechanism. Specifically, the researchers hope to understand whether these drugs can promote glucose transport through an insulin - independent pathway, thereby providing new insights into the treatment of type 2 diabetes. ### Research Background and Hypothesis 1. **GLP - 1 and Its Effects** - Glucagon - like peptide - 1 (GLP - 1) is a hormone secreted by intestinal L cells, which can stimulate insulin secretion and reduce glucagon release. - Exenatide (EXE) is a synthetic analogue of GLP - 1, used to treat type 2 diabetes, has a stronger hypoglycemic effect and is resistant to degradation by DPP - IV (dipeptidyl peptidase IV). 2. **The Role of AMPK** - AMPK is a protein activated under various physiological stimuli and is involved in regulating mitochondrial biogenesis, fatty acid synthesis, and glucose uptake. - The activation of AMPK is usually achieved by phosphorylating the Thr172 site of its α - subunit, which in turn affects downstream signaling pathways. ### Research Methods 1. **Cell Culture and Treatment** - Rat L6 skeletal muscle cells were used for the experiment, and the cells were exposed to 100 nmol/l of EXE or 100 nmol/l of insulin respectively. - Glucose uptake was measured by 2 - deoxy - glucose (2DG) uptake assay. - Western Blot was used to analyze the phosphorylation levels of AMPK and other related proteins. 2. **Exploration of Molecular Mechanisms** - The effects of EXE on signaling pathways such as insulin receptor (IR), IRS - 1, PI3K, AKT, ERK1/2, and JNK1/2 were detected. - The role of AMPK in EXE - induced glucose uptake was verified by inhibiting AMPK activity (using compound C) or knocking down AMPK expression (using siRNA). ### Main Findings 1. **EXE Increases Glucose Uptake** - EXE significantly increased 2DG uptake in L6 myotubes within 20 minutes, with an effect comparable to that of insulin, and this effect could last for 48 hours. - The combined use of EXE and insulin did not produce a superimposed effect. 2. **EXE Activates AMPK** - EXE significantly increased the phosphorylation of the AMPK α - subunit at the Thr172 site, while having no obvious effect on the phosphorylation of IR, IRS - 1, PI3K, AKT, ERK1/2, and JNK1/2. - Inhibiting AMPK activity or knocking down AMPK expression completely eliminated EXE - induced 2DG uptake. 3. **The Role of EXE in Insulin - Resistant Cells** - EXE was still able to increase glucose uptake in methylglyoxal (MGO) - induced insulin - resistant L6 myotubes, indicating that its action is independent of the insulin signaling pathway. ### Conclusions 1. **Main Conclusions** - In L6 myotubes, EXE and Lira increase glucose uptake by activating AMPK, and this process is independent of the insulin signaling pathway. - This finding provides new mechanistic support for the application of GLP - 1 receptor agonists in the treatment of type 2 diabetes. 2. **Potential Significance** - This study reveals a new mechanism by which GLP - 1 receptor agonists increase glucose uptake through an AMPK - mediated pathway, providing a theoretical basis for the development of new diabetes treatment methods. Through these research results, we can better understand the mechanism of action of GLP - 1 receptor agonists in improving glucose metabolism, thereby providing more effective treatment regimens for diabetic patients.